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Abstract 
Probiotics for the prevention of necrotizing enterocolitis have attracted a huge interest. 
Combined data from heterogeneous randomised controlled trials suggest that probiotics 
may decrease the incidence of NEC. However, the individual studies use a variety of 
probiotic products, and the group at greatest risk of NEC, i.e. those with a birth weight of 
less than 1000g, are relatively under-represented in these trials so we do not have 
adequate evidence of either efficacy or safety to recommend universal prophylactic 
administration of probiotics to premature infants. These problems have polarized 
neonatologists, with some taking the view that it is unethical not to universally administer 
probiotics to premature infants, whereas others regard the meta-analyses as flawed and 
that there is insufficient evidence to recommend routine probiotic administration. 
Another problem is that the mechanism by which probiotics might act is not clear, 
although some experimental evidence is starting to accumulate. This may allow 
development of surrogate endpoints of effectiveness, refinement of probiotic regimes, or 
even development of pharmacological agents that may act through the same mechanism. 
Hence, although routine probiotic administration is controversial, studies of probiotic 
effects may ultimately lead us to effective means to prevent this devastating disease. 
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Although necrotizing enterocolitis (NEC) is one of the most common life-threatening 
surgical diseases affecting neonates, we still do not completely understand the 
pathogenesis, or how to prevent or treat the disease [1]. The mortality for surgical NEC 
remains high, at around 30% [2,3], and although therapies such as stem cells provide 
some promise [4], unless there is a major novel development, it is unlikely that 
improvements in the surgical or medical treatment of unstable infants with major gut 
necrosis will significantly reduce this mortality [5]. Survivors of acute NEC may have 
long-term morbidities related both to gut necrosis (e.g. short bowel syndrome [6]) and 
systemic sequelae (e.g. adverse neurodevelopmental outcome [7]). Given the morbidity 
and mortality and the lack of specific treatment, there is an urgent need for development 
of preventative strategies. A huge amount of interest and hope bordering on evangelism 
has been invested in the routine administration of probiotics to prevent or eradicate this 
disease. Neonatologists are quite polarized on the issue of probiotics to prevent NEC: 
proponents of probiotics regard the fact that probiotics are not routinely given to 
premature neonates as unethical, detractors regard the meta-analyses combining different 
probiotic strains as deeply scientifically flawed. The American Pediatric Surgical 
Association Outcomes and Clinical Trials Committee considered the level of evidence for 
routine probiotic supplementation and concluded that ‘Substantial data support routine 
supplementation of enteral intake with probiotics in premature infants to reduce the 
incidence of severe NEC (Grade A/B). No formal recommendations regarding the 
formulation, timing or duration of supplementation could be determined, but at least one 
probiotic formulation initiated in the first week of life and continued for at least two 
weeks appears appropriate.’ [8]. However, it was also noted in this review that ‘No 
conclusions regarding probiotic use in ELBW (< 1000 grams) infants could be 
extrapolated from the studies due to limited data.’ 
The aims of this review article are to discuss the rationale for the administration of 
probiotics to prevent NEC, the scientific basis for their action, and briefly discuss the 
current evidence for effectiveness.  
Pathogenesis of NEC 
Although the pathogenesis of NEC is incompletely understood, there are several 
established risk factors, including prematurity, altered intestinal blood flow / oxygen 
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delivery, formula (as opposed to human breast milk) feeding, immature immune 
responses and a bacterial component. While the precise role of bacterial agents in the 
development of NEC is unclear, several factors implicate their involvement. Occasionally 
NEC is observed to occur in clusters, in which a higher than expected number of cases 
are observed in one centre [9]. Identical organisms are grown from babies within these 
clusters and the initiation of infection control measures has been shown to control such 
outbreaks [10]. However, different organisms are grown from separate outbreaks so it 
cannot be claimed that a single organism is involved in development of NEC. Bacterial 
involvement in the pathogenesis of NEC is also implicated by association; endotoxaemia 
[11,12] and positive blood cultures are common in infants with NEC and the 
gastrointestinal pneumatosis found in NEC contains 30% hydrogen [13], a gas produced 
solely by bacterial metabolism. Recent work implicating bacteria in the pathogenesis of 
NEC has also come from studies suggesting that NEC can be predicted before onset of 
clinical symptoms by analysis of fecal volatile organic compounds, which are likely to 
originate from intestinal microbiota [14,15]. However, colonization of the neonatal 
intestine is a complex process, and before considering the impact of probiotic 
administration on the incidence of NEC, it is important to consider the microbiome of the 
premature infant. 
 
The Infant Microbiome 
The adult human harbours a rich and diverse microbial community.  It is estimated that 
microbes in the human body collectively outnumber human cells by a factor of 10 to 1 
and that they encode for 100-fold more unique genes than our own genome [16].  The 
vast majority of these microbes are found in the gastrointestinal tract which is estimated 
to contain more than 1000 prevalent bacterial species [17].  Intestinal bacteria and 
humans usually establish a mutual relationship with each other.  This relationship is 
encapsulated by the word commensal which originates from the Latin cum mensa or 
‘sharing a table’[18] . In return for providing a stable environment that is rich in energy 
sources derived from ingested food, intestinal microbiota provide important functions 
such as nutrient acquisition and energy regulation by breaking down otherwise 
indigestible food [19].  They also play a number of protective roles which include: 
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development of the intestinal epithelium; limitation of pathogen colonisation by 
competing for adherence to epithelial surfaces; production of antimicrobial compounds; 
and regulation of intestinal immune responses [20].  Our natural microbial community 
evolves with us and plays a significant role in both health and disease.  Changes in our 
microbiome have been implicated in a range of pathological conditions from obesity 
through to inflammatory bowel disease [21-23].   
 
The original belief (first hypothesised at the turn of the 20
th
 century) that humans develop 
within a sterile uterine environment [24] has more recently been challenged by increasing 
evidence that the infants’ initial inoculum can be provided by maternal transmission 
before birth [25].   Further evidence refuting the belief that an infant’s intestine is sterile 
at birth comes from the recent identification of numerous microorganisms in meconium 
[26].  The early establishment of an infants’ microbiota is very unstable [27] and is 
influenced by a number of factors [28].  The most important of these factors likely 
include the mode of delivery [29] and feeding type during the initial post-partum period 
[30].  Vaginally delivered babies acquire their mothers’ vaginal flora at birth (by contrast, 
babies delivered by Caesarean section are colonised with bacterial communities 
resembling the skin) [29,31].  Following initial inoculation, culture based studies suggest 
that aerobic species such as Enterobacteriaceae, staphylococci and streptococci become 
established early colonisers during the first 2-3 days and their presence creates an 
anaerobic environment which facilitates the growth of species such as Clostridia, 
Bacteroides and Bifidobacteria [32].  Breastmilk is an additional rich source of microbes 
[33].   By the end of the first week after birth, Bifidobacteria dominate the flora of breast 
fed infants with formula fed infants harbouring a more heterogeneous intestinal microbial 
community [34].  During infancy, a unique balance is formed by gastrointestinal 
microbes and host tolerance and diet, all of which influence the acquisition and eventual 
stability of the intestinal microflora [35]. 
 
In preterm babies, the normal succession of bacterial colonisers may be interrupted by a 
variety of factors.  Infants are usually nursed away from their mothers in the sterile and 
often hostile environment of the intensive care unit.  Birth by caesarean section, broad 
 6 
spectrum antibiotic administration, delayed initiation of feeds and placement of invasive 
catheters can interrupt the process of normal colonisation and result in a more restricted 
enteric microbiota with delayed colonisation by Bifidobacteria [36,37]. In contrast to 
term infants, the gastrointestinal tract of preterm babies lacks microbial diversity and 
frequently becomes colonised with limited numbers of bacterial flora.  It is often 
dominated by potentially pathogenic species including: Enterobacteria, E. coli, 
Bacteroides, Eenterococci, Streptococci, Staphylococci and Klebsiella [38,39]. As a 
commensal microbiome is self-perpetuating [40], so, similarly, is an abnormal 
microbiome, in the sense that a failure to establish a normal spectrum of commensals 
within the gut predisposes to further pathogenic colonisation.  Abnormal pathogenic 
intestinal microbiomes are characteristically less diverse than normal gut flora [41], and 
consequently do not induce the competitive environment which limits the influx of 
extrinsic pathogens.  Similarly, the aforementioned homeostatic behaviour of commensal 
organisms (i.e. inflammatory dampening, induction of self-sustaining nutrition) is absent, 
leading to instability of the microbiome. 
 
It has been suggested that the risk of developing NEC, (similar to other inflammatory 
bowel conditions like Chron’s disease) is increased when the balance between pathogenic 
and commensal bacteria shifts in favour of the former resulting in an abnormal 
microbiome.  This is facilitated through impairment of the natural barriers to bacterial 
translocation, creation of a pro-inflammatory milieu, and perpetuating an unstable 
microbiome, unfavourable to re-colonisation with commensals. Although no specific 
bacterial species have been associated with the development of NEC, studies have shown 
that the presence of some abnormal intestinal flora is associated with a greater risk of 
NEC [42].  Rather than a single causative agent, it is more likely that the composition or 
structure of the preterm intestinal bacterial community plays a role in disease 
development [43]. High throughput sequencing of bacterial flora from preterm infants 
shows that babies who develop NEC cluster separately from controls [44]. Furthermore, a 
close temporal relationship has been demonstrated between abnormal microbial 
colonisation patterns and NEC, with ‘blooms’ of pathogenic γ-proteobacteria seen to 
precede the onset of clinical NEC by several days [45]. With the advent of modern 
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pyrosequencing methods for microbiome analysis, we can expect more studies on the role 
of microbiota in the development of NEC. However, such data are very complex, and 
analysis of these data in a very heterogeneous disease like NEC is extremely challenging.  
Nevertheless, recent studies have suggested a loss in microbial diversity to occur 
immediately before NEC onset [46,47], with a consequent predominance of Escherichia 
spp. [46] or strict anaerobes [47]. 
 
Probiotics for the prevention of NEC 
 
In 1907, Nobel laureate Elie Metchnikoff proposed that yoghurt (containing probiotics) 
prolonged life [48].  The World Health Organisation defines probiotics as live organisms 
(bacteria and yeast) that, when ingested in sufficient amounts, have a beneficial effect on 
the overall health of the host [49].  Probiotics are derived from fermented foods, from 
beneficial commensals or from the environment and have been shown to act through 
diverse mechanisms from alteration of the commensal microbiota to modification of gut 
barrier function and intestinal immune responses [50].  Given their propensity for 
abnormal colonisation patterns, using probiotics to manipulate and potentially normalise 
the intestinal flora of preterm babies is an attractive therapeutic potential.  This 
intervention might have particular relevance to diseases such as NEC where, changes in 
the gut microbial community preceding the onset of symptoms, has previously been 
demonstrated [45,44].   
 
Proof of concept studies showing the ability of probiotic species to successfully colonise 
the preterm intestine began to emerge in the early 1990s [51].  Further evidence that 
probiotics might benefit preterm infants was reported by Kitajima and colleagues in 1997 
who, in addition to demonstrating successful recovery of this probiotic from stool also 
reported that its administration was associated with a reduction in apnoea and vomiting 
[52].  In 1999, Hoyos and colleagues reported the outcome of a cohort study, in which, 
probiotic administration was associated with a reduction in the incidence of necrotizing 
enterocolitis [53].  Between 2003 and 2006, several randomised studies reported a 
reduction in the incidence of NEC among preterm babies recruited to probiotic trials (and 
 8 
receiving the probiotic intervention) though not all these studies were designed to 
evaluate NEC as a primary outcome [54-59].  The first meta-analysis combining these 
results was published in 2007 and concluded that probiotics might reduce the risk of NEC 
in preterm babies born less 33 weeks gestation [60]. A further meta-analysis published by 
the Cochrane Collaboration in 2009 concluded that probiotics reduced the incidence of 
NEC in babies >1000g birth-weight [61].   
 
Despite these findings, enthusiasm for implementing the routine use of probiotics was 
hampered by numerous concerns.  These concerns centred around the heterogeneity of 
probiotics used in individual studies, lack of data relating to optimum dosing and timing 
of intervention, short and long term safety of probiotics and perhaps most importantly, 
the lack of evidence for benefit among infants who might be deemed most at risk of 
developing NEC [62-64] and in particular those <1000g.  Additional concerns were 
raised about the quality of trials included in various meta-analyses.  In 2012, Mihatsch 
and colleagues systematically analysed the level of evidence of published randomised 
controlled trials on probiotics in preterm babies in order to evaluate whether a statistically 
confirmatory basis could be provided to recommend routine probiotic use in very low 
birth weight babies (VLBW) to prevent NEC, sepsis, death and feeding tolerance.  This 
study applied robust and validated methods to assess the quality of individual trials used 
in prior meta-analyses and reported that only 2 of 15 trials provided Level of Evidence 
(LoB) 1b neither of which supported the use of probiotics in preterm babies [65].  In the 
absence of confirmatory studies, many researchers agreed that a number of these 
concerns could only be addressed by further large randomised controlled trials.        
 
In 2013, researchers from the University of Melbourne were the first to report the finding 
of the largest published neonatal probiotics trial to date [66].  This well designed study 
addressed many of the previous concerns raised in relation to smaller trials and as such, 
the importance of this study cannot be understated.  Most importantly, the authors 
reported a statistically significant reduction in NEC (Bell’s stage 2 or 3) among infants 
born at <32 weeks gestation and randomised to receive a probiotic intervention 
containing three probiotic species.  Infants who benefited most were those born at ≥28 
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week’s gestation and ≥1000g birthweight.  However, NEC development was a secondary 
outcome to this trial, the primary outcome of which was late onset sepsis.  
 
The results of further large trials recruiting a more appropriate target patient group are 
eagerly awaited. One such study (The UK based PIPs trial) was designed with a primary 
outcome of sepsis, NEC or death, and recruited 1315 infants <31 weeks completed 
gestation [67] in England. This trial may provide further insight into the role of probiotics 
in the more immature preterm population. .  
 
 
The most recent updated Cochrane review on the use of probiotics in preterm babies 
includes more than 20 studies involving >5000 babies and includes data from the 
Australian ProPrems study. The reviewers conclude that enteral supplementation of 
probiotics prevents severe NEC and all-cause mortality in preterm babies [68].  But the 
evidence of benefit for babies born <1000g birthweight (those babies deemed most at risk 
for NEC) remains less clear. 
Safety of probiotics in preterm infants 
Concerns about short and long term safety of using currently available probiotic 
interventions remain.  Although some commentators have suggested that probiotic 
interventions should be considered separate to drug trials (because they are readily 
available as health supplements) [69] others have cautioned about the potential risks 
associated with their use  [70].  Standard culture techniques do not reliably detect 
probiotic bacteria so sepsis due to probiotic micro-organisms may be under-reported. 
Hence, crucially, it cannot be concluded that probiotics are either effective or safe in the 
highest risk population. The case for addressing safety concerns is particularly important 
given the recent identification of Rhizopus oryzae in unopened probiotic containers and 
the death of a preterm baby from invasive fungal disease  
(http://www.fda.gov/Food/RecallsOutbreaksEmergencies/Outbreaks/ucm423830.htm).  
The product implicated in this case is the same as that used in two previous randomised 
trials [56,66] (one of which was the large Australian ProPREMS study) though neither of 
these groups reported any serious events during the course of their trials.  Adverse events 
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associated with using bacteria to manipulate the flora of premature babies have 
previously been described.  During the 1960s numerous papers reported the efficacy of an 
apparent avirulent strain of Staphylococcus aureus 502A in aborting outbreaks of 
staphylococcal disease through the phenomenon of bacterial interference [71].  But the 
reported benefits were short-lived when the increasing use of this intervention was 
associated with the development of pustules in a high proportion of treated infants 
attributable to a mutated form of the bacteria [72].   
 
 
Mechanistic basic science studies on probiotics 
One aspect that contributes to unease regarding clinical uptake of probiotics, but might 
ultimately help to define a product, is the lack of mechanistic understanding of how 
probiotics might prevent NEC. The literature on potential mechanisms of probiotic action 
is mainly from experimental models. Although there are various experimental models of 
NEC, and several have been used to examine the effects of probiotics in NEC, none seem 
to completely recapitulate the human condition [73]. Data from a clinically relevant 
model (spontaneous NEC in premature pigs) hint as to why routine introduction of 
probiotics is less than straightforward. In 2 separate studies, by the same group, divergent 
results were obtained [74,75]. In one study, probiotics decreased severity of NEC lesions 
(but did not affect incidence) [74], whereas in the other, probiotics significantly increased 
the incidence and severity of NEC [75]. These differing results illustrate in a microcosm 
the multifactorial and unpredictable nature of NEC and why we might not always expect 
consistent effects from probiotic administration to premature infants with very different 
microbiota. 
A general assumption is that probiotics may reduce the incidence of NEC by altering the 
gut microbiome in favour of a more ‘friendly’ population of bacterial species which in 
turn reduces the risk of NEC. However, alteration of gut flora is only one potential 
mechanism by which probiotics might prevent NEC. Other mechanisms include effects 
on the gut immune system and via TLR-related signaling [76,77] and effects on mucosal 
integrity and intestinal permeability [78,79]. However, whether these are primary or 
secondary effects is extremely difficult to dissect, as the microbiome, immune system, 
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mucosal integrity and gut barrier function are all mutually interdependent. Mechanistic 
studies in human infants are clearly difficult, but the group of Walker and Nanthakumar 
[80] has established protocols using immature human intestine that provides mechanistic 
insights. In one of these, intestinal tissue from therapeutic terminations of pregnancy is 
implanted in immune-deficient mice, the xenografts allowed to mature for 20 or 30 weeks 
to model immature intestine (i.e. susceptible to NEC) or mature intestine respectively, 
and then challenged with inflammatory stimuli. In addition, enterocytes were isolated 
from resected ileum of an infant with NEC. Using these model systems, probiotic 
bacteria decreased inflammation, but, intriguingly, these effects could be reproduced by a 
small soluble factor produced by the probiotic bacteria. These data are supported by 
further studies which suggest that soluble factors secreted by Bifidobacterium infantis 
and Lactobacillus acidophilus are effective in preventing enterocyte damage [81,82].  If 
this soluble factor(s) were to be identified, it might be possible to use this factor 
pharmacologically for NEC prophylaxis, which may be easier to get accepted into routine 
clinical practice than a pot pourri of probiotics. Intriguingly, it has recently been 
suggested that the bacterial DNA alone of the probiotic strain Lactobacillus rhamnosus 
HN001 is sufficient to protect against NEC in a mouse model via activation of the TLR9 
pathway [83]. A greater mechanistic understanding of the actions of probiotics may also 
allow development of surrogate endpoints of effectiveness, and refinement of probiotic 
regimes, as well as development of pharmacological agents. 
   
Prebiotics and synbiotics 
Other terms which have been used in connection with prevention of NEC, although 
neither are well researched, are ‘prebiotics’ and ‘synbiotics’. Prebiotics are essentially 
dietary fibre, i.e. complex carbohydrates that are not readily digestible, but that are 
digestible by probiotic micro-organisms. Synbiotics are products that contain both 
prebiotics and probiotics, where the prebiotic acts synergistically as a substrate for the 
administered probiotic. Thus either prebiotics alone or synbiotics could also have 
beneficial effects on the microbiome of the premature infant. The only RCT addressing 
whether prebiotics or synbiotics can prevent NEC in premature infants showed that the 
rate of NEC was lower in pro- and syn- biotic supplemented infants than in prebiotic 
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supplemented or control infants. There was no evidence to support a benefit of synbiotic 
over probiotic supplementation [84].  
 
Other concepts 
Whilst the focus of scientific attention to date has been on the primary prevention of NEC 
by the use of probiotics, there are other related clinical scenarios in which there could be 
rationale for probiotic administration. One such scenario is following an episode of NEC 
since there is the potential for the use of probiotics after an episode of NEC to reduce the 
incidence of recurrent disease. Typical treatment for NEC includes 5-10 days ‘nil-by-
mouth’ with administration of broad spectrum antibiotics, after which enteral feeds are 
cautiously re-introduced. A proportion of these infants go on to experience further 
episodes of NEC. Whilst it is not clear how many infants with early NEC experience 
recurrent episodes, approximately 10% of infants with advanced NEC have recurrence 
[18]. This period of refeeding following a period of antibiotic ‘cleansing’ may provide an 
opportunity to use probiotics to redress the balance of the intestinal microbiome in favour 
of ‘friendly’ bacteria, and possibly decrease the incidence of recurrent NEC. To our 
knowledge there have been no studies to date that have examined this issue; such initial 
studies would necessarily have a primary aim of safety. 
 
 
 
Conclusions 
There is no doubt that the use of probiotics offers an exciting potential to reduce 
important complications of prematurity including NEC but no studies to date have been 
conducted that can causally link clinical improvements to probiotic induced changes in 
the microbiota.  We know that NEC is a complex disease, and that the intestinal 
microbiome is extremely intricate. Maybe the message from the sometimes confusing 
meta-analyses and RCTs is that we are being a little naïve in expecting a single probiotic 
to work like a drug, when it is in fact quite a complicated intervention. It is possible that 
providing a balanced mixture is beneficial – a parallel can be made with the ability of 
fecal microbiota transplantation to prevent recurrent C. difficile infection. Ongoing 
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randomised studies underpinned by studies of mechanistic action and robust long term 
follow-up are needed to address the many important unanswered questions that remain, 
that include (i) which probiotic strains to use?; (ii) when to administer?; (iii) who will 
benefit; and (iv) who might we harm.  
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